Idorsia submits NDA for clazosentan to Japanese PMDA
Allschwil, Switzerland – March 1, 2021
Idorsia Ltd (SIX: IDIA) today announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH).
The application is supported by replicated results from the Japanese registration program which consisted of two double-blind, randomized, placebo-controlled studies assessing the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality events in adult Japanese patients following aSAH. Patients were randomized to receive continuous infusion of either 10 mg/hr clazosentan or placebo for up to 15 days following the onset of aSAH. The two studies followed the same design, with one enrolling 221 patients whose aneurysm was secured by surgical clipping and the other enrolling 221 patients whose aneurysm was secured by endovascular coiling.
Satoshi Tanaka, Dr Med Sci. and President of Idorsia Pharmaceuticals Japan, commented:
“The development of clazosentan has taken many years to bring us to the filing of an NDA and we were very fortunate to not be held back by the COVID-19 pandemic in Japan. The team has worked rapidly to analyze the data and prepare the dossier for the PMDA so that we can bring clazosentan to the patients as soon as possible. We will now work together with the authorities through the regulatory process, and in parallel, prepare the scientific publication and the commercial launch which we hope to see in the first half of 2022.”
Both studies showed that clazosentan reduced the occurrence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH with statistical significance (p<0.01 for both studies). The composite endpoint was defined by at least one of the following: All death / New cerebral infarction due to cerebral vasospasm / Delayed ischemic neurologic deficit due to cerebral vasospasm and adjudicated blindly by an independent committee. The effect of clazosentan on all-cause morbidity and mortality was also significant (p<0.05) in a pre-planned analysis of the pooled studies whereas a numerical trend was observed in each study on this endpoint.
The studies confirmed the well-documented safety profile of clazosentan which has now been administered to approximately 2000 patients around the world. In these registration studies in Japanese patients post-aSAH there were no unexpected safety findings. Treatment-emergent adverse events occurring in >5% of the clazosentan group (with a difference of >2% compared to placebo) were vomiting and signs of hemodilution or fluid retention (i.e., hyponatremia, hypoalbuminemia, anemia, pleural effusion, brain and pulmonary edema).
Notes to the editor
Available data in Japanese patients
A Phase 2 study in Japanese and Korean patients showed that 10 mg/hr of clazosentan administered by continuous intravenous infusion significantly reduced vasospasm and vasospasm-related morbidity and mortality events. The results are published in Cerebrovascular Diseases (Fujimura M, et al. Cerebrovasc Dis 2017;44:59–67). On that basis, a registration program was initiated with clazosentan in Japan in May 2016.
About the global registration program “REACT”
In February 2019, Idorsia initiated REACT, a prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in adult patients following aSAH. The Phase 3 study builds upon the learnings from the previous clazosentan studies to identify patients at high risk of vasospasm and delayed cerebral ischemia, the optimal dose, the best measure to demonstrate efficacy and an optimized patient management guideline to ensure patient safety.
Approximately 400 patients – treated either with microsurgical clipping or endovascular coiling – are being enrolled at approximately 95 sites across 15 countries. Patients are randomized to receive continuous infusion of either clazosentan (15 mg/hr) or placebo prophylactically, on top of local standard of care, for a period of up to 14 days. REACT is enrolling aSAH patients identified as being at high risk of developing vasospasm and subsequent delayed cerebral ischemia because of high-volume hemorrhage, as assessed by CT scan on hospital admission. Patients experiencing asymptomatic cerebral vasospasm, as measured by angiography, within 14 days of aSAH may also be included. Results of the study are targeted for the second half of 2022.
About aneurysmal subarachnoid hemorrhage and cerebral vasospasm
Aneurysmal subarachnoid hemorrhage is a rare condition involving sudden life-threatening bleeding occurring in the subarachnoid space. It is caused by the rupture of an aneurysm – a weak, bulging spot on the wall of a cerebral artery. Emergency surgical repair (endovascular coiling or microsurgical clipping) is required to stop the hemorrhage.
The bleeding and the release of a vasoconstrictor (endothelin) by the neighboring vascular endothelium can lead to cerebral vasospasm (constriction of arteries in the brain), usually occurring between 4 and 14 days after aneurysm securing. This diminishes blood flow to the brain, and about one third of patients consequently experience worsening of their neurological condition. Cerebral vasospasm is one of the leading secondary causes of disability and death in patients with aSAH.
The incidence of aSAH is estimated to be between 6 and 9 per 100,000 per year worldwide. Notably, aSAH is a significant problem in Japan, with an incidence at least twice as high as in many other countries of the world.
Approximately 50% of the overall aSAH population present with thick, diffuse blood clots characterized by a large amount of subarachnoid blood on the admission CT scan. These patients have a significantly higher risk of experiencing cerebral vasospasm.
Available clinical data with clazosentan
Several studies have built our understanding of the role of clazosentan in preventing or reversing cerebral vasospasm.
In 2006, results were reported for clazosentan in the prevention of angiographic vasospasm in patients with aSAH. The Phase 2 dose-finding study, CONSCIOUS-1, demonstrated dose-dependent prevention of vasospasm.
This was followed by two Phase 3 studies, CONSCIOUS-2 and CONSCIOUS-3, to assess the effect of clazosentan on the incidence of cerebral vasospasm-related morbidity and all-cause mortality. In 2010, CONSCIOUS-2 showed that the 5 mg/h dose of clazosentan, administered by continuous intravenous infusion, did not allow a statistically significant treatment effect to be observed, resulting in the premature termination of CONSCIOUS-3. However, an exploratory analysis of the data collected in CONSCIOUS-3 showed that a higher dose of clazosentan (15 mg/h), administered by continuous intravenous infusion, significantly reduced cerebral vasospasm-related morbidity and all-cause mortality, with a 44% relative risk reduction (p=0.0074).
The 15 mg/h dose also significantly reduced the incidence of delayed ischemic neurological deficit, with a 54% relative risk reduction (p=0.0038). In addition, clazosentan reduced the need for rescue therapy for vasospasm. Clazosentan did not improve long-term clinical outcome.
A Phase 2 study in Japanese and Korean patients showed that 10 mg/hr of clazosentan significantly reduced vasospasm and vasospasm-related morbidity and mortality events.
A pilot study evaluating the early effect of clazosentan on reversing established cerebral vasospasm in large proximal cerebral artery segments at 3 hours post initiation suggests that, with early administration, clazosentan has the potential to improve large-vessel vasospasm. In a post-hoc analysis of the effect of clazosentan on reversing established cerebral vasospasm in the entire cerebral vasculature (including smaller distal vessel segments and the cerebellar arteries), a clearly visible improvement was observed in vessel diameter at 3 and 24 hours.
The studies confirmed the well-documented safety profile of clazosentan, which has now been administered to approximately 2000 patients around the world. The side effects of clazosentan are managed based on clear protocol guidelines: hypotension can be mitigated using blood pressure control with vasopressors in the ICU, while lung complications (such as pulmonary edema) can be managed by aiming to maintain euvolemia by avoiding excessive fluid administration.
Fujimura M, et al. Cerebrovasc Dis 2017; 44:59–67
Macdonald R L, et al. Stroke. 2012; 43(6):1463-9.
Macdonald R L, et al. The Lancet. Neurology, 2011; 10(7):618-625.
Macdonald R L, et al. Stroke 2008; 39:3015-3021.
Vajkoczy P, et al. Journal of Neurosurgery 2005; 103:9-17.
Roux S. et al. J Pharmacol Exp Ther 1997; 283:1110-1118.
Clozel M, Watanabe H, Life Sciences 1993; 52(9):825-834
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets.
About Idorsia Pharmaceuticals Japan
Idorsia Pharmaceuticals Japan was established, under the leadership of Dr Satoshi Tanaka, in 2018 to conduct clinical development and prepare the commercialization of Idorsia's innovative and promising compounds for patients in Japan.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag23.4.2021 17:57:11 CEST | Press release
Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 23 April 2021, purchased 100 shares of RomReal at NOK 1.85 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,544,127 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
GrandVision's Annual General Meeting (AGM) 2021 adopts all resolutions23.4.2021 16:30:00 CEST | Press release
GrandVision's Annual General Meeting (AGM) 2021 adopts all resolutions Schiphol, the Netherlands - 23 April 2021. GrandVision N.V. (Euronext: GVNV) announced today that its Annual General Meeting (AGM) has approved all resolutions on the agenda of the AGM. The adopted resolutions are listed below: • Adoption of the Annual Accounts for the financial year 2020 as drawn up by the Management Board and signed by the Managing Directors and the Supervisory Directors on 25 February 2021 • Advisory vote on the approval of the remuneration report 2020 • Proposal on dividend distribution for the financial year 2019 of EUR 0.35 per share • Discharge of Managing Directors for their management during the financial year 2020 • Discharge of Supervisory Directors for their supervision of management during the financial year 2020 • Re-appointment of Mr. P. Bolliger as Supervisory Board Director • Re-appointment of Mr. J. Cole as Supervisory Board Director • Appointment of PricewaterhouseCoopers Accounta
CONDITIONS FOR PURCHASES OF CORPORATE BONDS23.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-28BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: VACSE AB: SE0010833012, 2023-09-12 VACSE AB: SE0011062876, 2022-06-07 VASAKRONAN AB: XS1941844174, 2022-02-11 VASAKRONAN AB: XS2048590439, 2022-11-29 NOBINA: SE0012194165, 2024-02-13 VOLVO TREASURY AB: XS2075216395, 2022-11-04 VOLVO TREASURY AB: XS1921474844, 2023-12-13 HOLMEN AB: SE0011426238, 2023-11-24 HOLMEN AB: SE0011281567, 2022-05-23 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-03-28Bid date2021-04-28Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0010833012: 30 mln SEK +/-30 mln SEK SE0011062876: 30 mln SEK +/-30 mln SEK XS1941844174: 30 mln SEK +/-30 mln SEK XS2048590439: 30 mln SEK +/-30 mln SEK SE0012194165
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS23.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-27BondsKOMMUNINVEST I SVERIGE: 2505. SE0011414010. 2025-05-12 KOMMUNINVEST I SVERIGE: 2611, SE0012569572, 2026-11-12 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2021-04-27Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2505: 750 mln SEK +/-350 mln SEK 2611: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)2505: 750 mln SEK per bid 2611: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-04-29Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases of Bonds via Bid Procedure 2020:3. dated 20 November 2020 (see the Riksbank´s web). S
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS23.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-29BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 144., SE0011167428, 2023-06-21 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 519, SE0012324341, 2026-09-16 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 Bid date2021-04-29Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 800 mln SEK +/-400 mln SEK 1591: 2000 mln SEK +/-1000 mln SEK 144.: 700 mln SEK +/-350 mln SEK 580: 700 mln SEK +/-350 mln SEK 519: 600 mln SEK +/-300 mln SEK 2312: 200 mln SEK +/-100 mln SEK 5535: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 800 mln SEK per bid 1591: 2000 mln SEK per bid 144.: 700 mln SEK per bid 580: 700 mln SEK per bid 519: 600 mln SEK per bid 2312: 200 mln SEK per bid 5535: 1000 mln SEK per bid Lowest permitted bid volu
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER23.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-28CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-10-28 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-04-16 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-04-28Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
New Bitwats ASIC Miners Disrupts Crypto Market23.4.2021 14:36:41 CEST | Press release
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- The rapidly evolving global market for cryptocurrency is currently abuzz with the recent introduction of three extraordinarily designed mining rigs, BT, DBT and GBT from BitWats (www.bitwats.com). Instead of focusing only on highly proficient and technology savvy mining stalwarts, these three products were created to allow the casual enthusiasts as well as small-time miners to make their fortune out of crypto mining. DBT offers hash rates of 750 TH/s, 70 GH/s, 5 GH/s, and 5 MH/s, for bitcoin, litecoin, ethereum, and monero respectively. On the other hand, for GBT Miner, the hash power in the same order are 2250 TH/s, 210 GH/s, 15 GH/s, and 15 MH/s. The power consumptions for these two units are 900W and 2200W respectively. Based on figures mentioned above, monthly profit making potential of the two units is as mentioned below. DBT Miner: $7,500 (Bitcoin), $13,000 (Litecoin), $13,000 (Ethereum), and $15,000 (Monero)GBT Miner: $22,500 (Bitcoin